



Fresenius Medical Care

JUN 15 2007

**Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrate
"Special" 510(k) Premarket Notification**

510(k) Summary

A. Submitter's Information:

Name: Fresenius Medical Care North America
Address: 920 Winter Street
Waltham, MA 02451

Phone: (781)699-4475
Fax: (781) 699-9635
Contact Person: Janet C. Kay, Manager Regulatory Affairs
Date of Preparation: June 14, 2007

B. Device Name:

Trade Name: Naturalyte® Sodium Bicarbonate Liquid Concentrate
Common/Usual Name: Dialysate Concentrate for Hemodialysis (liquid)
Classification Name: Hemodialysis systems and accessories



Fresenius Medical Care

Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrate "Special" 510(k) Premarket Notification

510(k) Summary

C. Predicate Device Name:

The Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrate is a modified version of the Fresenius Biosol Powder Bicarbonate Concentrate

- #K981043 (5/26/1998)

D. Device Description/Indications for Use:

The intended use for the modified device is equivalent to that of the unmodified device:

Intended Use

This concentrate is formulated to be used with a three steam hemodialysis machine which is calibrated for acid and bicarbonate concentrates

E. Substantial Equivalence:

Substantial Equivalence Decision Making Process

1. Is the product a device?

YES - The Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrate is a device pursuant to 21 CFR §201 [321] (h).

2. Does the new device have the same intended use?

YES – The intended use for the modified device is equivalent to the unmodified device.

Fresenius modified Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrates - Intended Use

This concentrate is formulated to be used with a three steam hemodialysis machine which is calibrated for acid and bicarbonate concentrates

Fresenius unmodified Biosol Powder Bicarbonate Concentrate - Intended Use

This concentrate is formulated to be used with a three steam hemodialysis machine which is calibrated for acid and bicarbonate concentrates

JUN 15 2007



K071387 Page 3 of 3

Fresenius Medical Care

Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrate "Special" 510(k) Premarket Notification

510(k) Summary

3. Does the device have technological characteristics that raise new types of safety or effectiveness questions?

NO – The Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrates is a modified versions of the Biosol Powder Bicarbonate Concentrates. The technological characteristics of the modified devices are equivalent to those of the unmodified devices and raise no new types of safety or effectiveness questions.

4. Does descriptive or performance information demonstrate equivalence?

YES – Fresenius Medical Care North America believes that the information provided in this submission clearly describes the modified Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrate and demonstrates that it is substantially equivalent to the unmodified devices.

F. Safety Summary

The Fresenius modified Naturalyte® Sodium Bicarbonate Liquid Concentrate is substantially equivalent in chemical formulation, chemical composition, and intended use to the commercially available Biosol Powder Bicarbonate Concentrates currently distributed as Fresenius Naturalyte® Dry Pack Bicarbonate Concentrates. In addition, testing of the modified device indicates that the formulations are safe and effective for its intended use.

G. General Safety and Effectiveness Concerns

The Fresenius modified Naturalyte® Sodium Bicarbonate Liquid Concentrates are to be used with a three-stream proportioning systems when calibrated to specified proportions depending on the series and mixed with water that meet ANSI/AAMI RD 62.. Use with other equipment or without associated bicarbonate concentrate may cause patient injury or death. Not for Parenteral Use.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
9200 Corporate Blvd.
Rockville MD 20850

Ms. Janet C. Kay
Manager of Regulatory Affairs
Fresenius Medical Care North America
920 Winter Street
WALTHAM MA 02451

JUN 15 2007

Re: K071387
Trade/Device Name: Fresenius Naturalyte[®] Sodium Bicarbonate Liquid
Concentrates, (4000 Series)
Regulation Number: 21 CFR §876.5820
Regulation Name: Hemodialysis system and accessories
Regulatory Class: II
Product Code: KPO
Dated: May 16, 2007
Received: May 18, 2007

Dear Ms. Kay:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.



Protecting and Promoting Public Health

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.


This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

21 CFR 876.xxxx	(Gastroenterology/Renal/Urology)	240-276-0115
21 CFR 884.xxxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 892.xxxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>

Sincerely yours,



Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure



Fresenius Medical Care

Indications for Use

510(k) Number (if known): K071387

Device Name:

Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrates, 4000 Series.

Indications for Use:

This concentrate is formulated to be used with a three steam hemodialysis machine which is calibrated for acid and bicarbonate concentrates

Prescription Use
 (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use
 (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)

Division of Reproductive, Abdominal,
and Radiological Devices

510(k) Number K071387

Page of

(Posted November 13, 2003)

Fresenius Medical Care North America

Corporate Headquarters: 920 Winter Street Waltham, MA 02451 (781) 699-9000